Hypothemicin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei

eLife

Volumn 2013, Issue 2, 2013, Pages

  Nishino, Mari ^a,b   Choy, Jonathan W ^a   Gushwa, Nathan N ^a   Oses Prieto, Juan A ^a   Koupparis, Kyriacos ^a   Burlingame, Alma L ^a   Renslo, Adam R ^a,b   McKerrow, James H ^b,c   Taunton, Jack ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California at San Francisco   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOTHEMYCIN; AFFINITY LABELING; ANTIPROTOZOAL AGENT; ZEARALENONE;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LABELING; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FLUORESCENCE; IC 50; IMMUNOPRECIPITATION; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARASITE LOAD; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THIN LAYER CHROMATOGRAPHY; TRYPANOSOMA BRUCEI; TRYPANOSOMIASIS; WESTERN BLOTTING; AFFINITY LABELING; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FUNGUS; METABOLISM; TRYPANOSOMA BRUCEI BRUCEI; VALIDATION STUDY;

AFFINITY LABELS; ANTIPROTOZOAL AGENTS; FUNGI; MASS SPECTROMETRY; TRYPANOSOMA BRUCEI BRUCEI; ZEARALENONE;

EID: 84880096320     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.00712     Document Type: Article

References (50)

1. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. 2008. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-46. doi: 10.1200/JCO.2007.14.4956.
2. Alsford S, Turner DJ, Obado SO, Sanchez-Flores A, Glover L, Berriman M, et al. 2011. High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome. Genome Res 21:915-24. doi: 10.1101/gr.115089.110.
3. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. 2007. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25:1035-44. doi: 10.1038/nbt1328.
4. Barluenga S, Jogireddy R, Koripelly GK, Winssinger N. 2010. In vivo efficacy of natural product-inspired irreversible kinase inhibitors. Chembiochem 11:1692-9. doi: 10.1002/cbic.201000205.
5. Choy JW, Bryant C, Calvet CM, Doyle PS, Gunatilleke SS, Leung SSF, et al. 2013. Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target. Beilstein J Org Chem 9:15-25. doi: 10.3762/bjoc.9.3.
6. Domenicali Pfister D, Burkard G, Morand S, Renggli CK, Roditi I, Vassella E. 2006. A Mitogen-activated protein kinase controls differentiation of bloodstream forms of Trypanosoma brucei. Eukaryot Cell 5:1126-35. doi: 10.1128/EC.00094-06.
7. Du C, McGuffin ME, Dauwalder B, Rabinow L, Mattox W. 1998. Protein phosphorylation plays an essential role in the regulation of alternative splicing and sex determination in Drosophila. Mol Cell 2:741-50. doi: 10.1016/S1097-2765(00)80289-0.
8. Fairlamb AH. 2003. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol 19:488-94. doi: 10.1016/j.pt.2003.09.002.
9. Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, et al. 2011. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol 18:67-76. doi: 10.1016/j.chembiol.2010.11.009.
10. Fevre EM, Wissmann BV, Welburn SC, Lutumba P. 2008. The burden of human African trypanosomiasis. PLOS Negl Trop Dis 2:e333. doi: 10.1371/journal.pntd.0000333.
11. Gourguechon S, Wang CC. 2009. CRK9 contributes to regulation of mitosis and cytokinesis in the procyclic form of Trypanosoma brucei. BMC Cell Biol 10:68. doi: 10.1186/1471-2121-10-68.
12. Guttinger A, Schwab C, Morand S, Roditi I, Vassella E. 2007. A mitogen-activated protein kinase of Trypanosoma brucei confers resistance to temperature stress. Mol Biochem Parasitol 153:203-6. doi: 10.1016/j.molbiopara.2007.02.001.
13. Horn D, McCulloch R. 2010. Molecular mechanisms underlying the control of antigenic variation in African trypanosomes. Curr Opin Microbiol 13:700-5. doi: 10.1016/j.mib.2010.08.009.
14. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. 2009. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461:614-20. doi: 10.1038/nature08356.
15. Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, Heuer D, et al. 2010. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463:818-22. doi: 10.1038/nature08760.
16. Kumar V, Schuck EL, Pelletier RD, Farah N, Condon KB, Ye M, et al. 2011. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. Cancer Chemother Pharmacol 69:229-37. doi: 10.1007/s00280-011-1687-8.
17. Lee J, Moir RD, McIntosh KB, Willis IM. 2012. TOR signaling regulates ribosome and tRNA synthesis via LAMMER/Clk and GSK-3 family kinases. Mol Cell 45:836-43. doi: 10.1016/j.molcel.2012.01.018.
18. Leproult E, Barluenga S, Moras D, Wurtz JM, Winssinger N. 2011. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem 54:1347-55. doi: 10.1021/jm101396q.
19. Li Z, Umeyama T, Wang CC. 2010. Polo-like kinase guides cytokinesis in Trypanosoma brucei through an indirect means. Eukaryot Cell 9:705-16. doi: 10.1128/EC.00330-09.
20. Ma J, Benz C, Grimaldi R, Stockdale C, Wyatt P, Frearson J, et al. 2010. Nuclear DBF-2-related kinases are essential regulators of cytokinesis in bloodstream stage Trypanosoma brucei. J Biol Chem 285:15356-68. doi: 10.1074/jbc.M109.074591.
21. Mackey ZB, Koupparis K, Nishino M, McKerrow JH. 2011. High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei. Chem Biol Drug Des 78:454-63. doi: 10.1111/j.1747-0285.2011.01156.x.
22. Mercer L, Bowling T, Perales J, Freeman J, Nguyen T, Bacchi C, et al. 2011. 2,4-Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach. PLOS Negl Trop Dis 5:e956. doi: 10.1371/journal.pntd.0000956.
23. Moellering RE, Cravatt BF. 2012. How chemoproteomics can enable drug discovery and development. Chem Biol 19:11-22. doi: 10.1016/j.chembiol.2012.01.001.
24. Muller IB, Domenicali-Pfister D, Roditi I, Vassella E. 2002. Stage-specific requirement of a mitogen-activated protein kinase by Trypanosoma brucei. Mol Biol Cell 13:3787-99. doi: 10.1091/mbc.E02-02-0093.
25. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, et al. 2004. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 279:24246-54. doi: 10.1074/jbc.M314298200.
26. Nett IR, Martin DM, Miranda-Saavedra D, Lamont D, Barber JD, Mehlert A, et al. 2009. The phosphoproteome of bloodstream form Trypanosoma brucei, causative agent of African sleeping sickness. Mol Cell Proteomics 8:1527-38. doi: 10.1074/mcp.M800556-MCP200.
27. Oduor RO, Ojo KK, Williams GP, Bertelli F, Mills J, Maes L, et al. 2011. Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads. PLOS Negl Trop Dis 5:e1017. doi: 10.1371/journal.pntd.0001017.
28. Ojo KK, Gillespie JR, Riechers AJ, Napuli AJ, Verlinde CL, Buckner FS, et al. 2008. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother 52:3710-7. doi: 10.1128/AAC.00364-08.
29. Ong SE, Schenone M, Margolin AA, Li X, Do K, Doud MK, et al. 2009. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci USA 106:4617-22. doi: 10.1073/pnas.0900191106.
30. Parsons M, Worthey EA, Ward PN, Mottram JC. 2005. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 6:127. doi: 10.1186/1471-2164-6-127.
31. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, et al. 2011. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol 18:699-710. doi: 10.1016/j.chembiol.2011.04.011.
32. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, et al. 2009. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374:56-64. doi: 10.1016/S0140-6736(09)61117-X.
33. Rastelli G, Rosenfeld R, Reid R, Santi DV. 2008. Molecular modeling and crystal structure of ERK2-hypothemycin complexes. J Struct Biol 164:18-23. doi: 10.1016/j.jsb.2008.05.002.
34. Rodgers JT, Haas W, Gygi SP, Puigserver P. 2010. Cdc2-like kinase 2 is an insulin-regulated suppressor of hepatic gluconeogenesis. Cell Metab 11:23-34. doi: 10.1016/j.cmet.2009.11.006.
35. Rodgers JT, Vogel RO, Puigserver P. 2011. Clk2 and B56beta mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. Mol Cell 41:471-9. doi: 10.1016/j.molcel.2011.02.007.
36. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. 2004. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3:1154-69. doi: 10.1074/mcp.M400129-MCP200.
37. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. 2005. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474-83. doi: 10.1200/JCO.2005.04.192.
38. Schimanski B, Nguyen TN, Gunzl A. 2005. Highly efficient tandem affinity purification of trypanosome protein complexes based on a novel epitope combination. Eukaryot Cell 4:1942-50. doi: 10.1128/EC.4.11.1942-1950.2005.
39. Schirmer A, Kennedy J, Murli S, Reid R, Santi DV. 2006. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc Natl Acad Sci USA 103:4234-9. doi: 10.1073/pnas.0600445103.
40. Simarro PP, Jannin J, Cattand P. 2008. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLOS Med 5:e55. doi: 10.1371/journal.pmed.0050055.
41. Tanaka H, Nishida K, Sugita K, Yoshioka T. 1999. Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor. Jpn J Cancer Res 90:1139-45. doi: 10.1111/j.1349-7006.1999.tb00688.x.
42. Tang Z, Luca M, Portillio J, Ngo B, Chang C, Wen T, et al. 2011. LAMMER kinase Kic1 is involved in pre-mRNA processing. Exp Cell Res 317:2308-20. doi: 10.1016/j.yexcr.2011.06.014.
43. Taylor JE, Rudenko G. 2006. Switching trypanosome coats: what's in the wardrobe? Trends Genet 22:614-20. doi: 10.1016/j.tig.2006.08.003.
44. Tu X, Kumar P, Li Z, Wang CC. 2006. An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei. J Biol Chem 281:9677-87. doi: 10.1074/jbc.M511504200.
45. Tu X, Wang CC. 2004. The involvement of two cdc2-related kinases (CRKs) in Trypanosoma brucei cell cycle regulation and the distinctive stage-specific phenotypes caused by CRK3 depletion. J Biol Chem 279:20519-28. doi: 10.1074/jbc.M312862200.
46. Urbaniak MD. 2009. Casein kinase 1 isoform 2 is essential for bloodstream form Trypanosoma brucei. Mol Biochem Parasitol 166:183-5. doi: 10.1016/j.molbiopara.2009.03.001.
47. Urbaniak MD, Mathieson T, Bantscheff M, Eberhard D, Grimaldi R, Miranda-Saavedra D, et al. 2012. Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei. ACS Chem Biol 7:1858-65. doi: 10.1021/cb300326z.
48. Wang Z, Morris JC, Drew ME, Englund PT. 2000. Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters. J Biol Chem 275:40174-9. doi: 10.1074/jbc.M008405200.
49. Wee JL, Sundermann K, Licari P, Galazzo J. 2006. Cytotoxic hypothemycin analogues from Hypomyces subiculosus. J Nat Prod 69:1456-9. doi: 10.1021/np060258o.
50. Winssinger N, Barluenga S. 2007. Chemistry and biology of resorcylic acid lactones. Chem Commun (Camb) 22-36. doi: 10.1039/b610344h.